Edition:
United States

Molecular Medicine SpA (MLMD.MI)

MLMD.MI on Milan Stock Exchange

0.46EUR
27 Mar 2017
Change (% chg)

€-0.00 (-0.74%)
Prev Close
€0.46
Open
€0.46
Day's High
€0.46
Day's Low
€0.45
Volume
366,583
Avg. Vol
4,190,855
52-wk High
€0.64
52-wk Low
€0.29

Latest Key Developments (Source: Significant Developments)

Molmed FY net loss shrinks to 13.9 million euros
Tuesday, 7 Mar 2017 01:46am EST 

Molecular Medicine SpA : Reported on Monday FY operating revenues 22.8 million euros ($24.14 million) versus 16.8 million euros a year ago .FY net loss 13.9 million euros versus loss 20.8 million euros a year ago.  Full Article

MolMed and Rocket Pharma sign collaboration agreement for treatment of Fanconi Anemia
Monday, 27 Feb 2017 01:12am EST 

MolMed SpA : MolMed and Rocket Pharma establish a collaboration agreement in the field of gene therapy for the treatment of Fanconi Anemia . Rocket Pharma is a U.S. gene therapy company .MolMed will develop and manufacture the lentiviral vectors to be used for the ex-vivo transduction of hematopoietic stem cells, as part of the manufacturing process of Rocket's cellular therapy products.  Full Article

MolMed and TTY sign term sheet to commercialise Zalmoxis in certain Asian territories
Tuesday, 7 Feb 2017 11:45am EST 

MolMed SpA : MolMed and TTY Biopharm (TTY)sign a term sheet to commercialise Zalmoxis in certain Asian territories . Within June 30, the terms contained in the agreement shall be incorporated into a definitive contract . After the signature of the definitive contract, the application of marketing authorization of Zalmoxis in the interested territories will be carried-out by and at cost of TTY . TTY will eventually perform further clinical studies, if needed to obtain regulatory approval, and will conduct associated regulatory activities after marketing authorization .MolMed will supply TTY with Zalmoxis and receive upfront and milestone payments up to 13.5 million euros ($14.43 million) and double-digit royalty payments on annual net sales.  Full Article

Molmed issues first tranche of shares reserved to Societe Generale
Wednesday, 21 Dec 2016 12:35pm EST 

Molmed SpA :Says has issued 10,000,000 ordinary shares reserved to Societe Generale at a price 0.4246 euros ($0.4428) per share.  Full Article

MolMed signs term sheet with Megapharm to distribute Zalmoxis in Israel
Thursday, 1 Dec 2016 12:29pm EST 

Molecular Medicine SpA (MolMed) : Signs term sheet with Megapharm Ltd defining main terms and conditions for supply, registration, promotion and distribution of Zalmoxis in Israel . Zalmoxis is conditionally authorized by the European Commission for adult patients affected by leukemia or other high-risk hematological malignancies .Within April 30, 2017, the terms contained in agreement to be incorporated into a definitive contract, pursuant to which Megapharm Ltd will be appointed by MolMed SpA as the exclusive licensee, under certain terms and conditions, to market, sell and distribute Zalmoxis in Israel.  Full Article

MolMed exercises power to carry out capital increase of up to 42 mln shares
Wednesday, 16 Nov 2016 03:49am EST 

MolMed SpA :Said on Tuesday that the board exercised the power to carry out the capital increase to be reserved to Societe Generale of up to 42,000,000 ordinary shares and within the limit of 10 percent of the existing share capital.  Full Article

MolMed Q3 net loss widens to EUR 5.9 mln
Tuesday, 8 Nov 2016 05:37am EST 

MolMed SpA : Reported on Monday Q3 net loss of 5.9 million euros ($6.52 million) versus loss 5.3 million euros a year ago .Q3 operating revenue of 3.7 million euros versus 3.1 million euros a year ago.  Full Article

MolMed announces review of strategic agreement with GlaxoSmithKline
Thursday, 1 Sep 2016 12:10pm EDT 

MolMed SpA : Announces amendment of strategic agreement signed with GlaxoSmithKline (GSK) on March 19, 2015 . Agreement relates to MolMed's supply of services for the clinical application of gene therapies based on viral vector cellular transduction until March 31, 2020 . To be eligible, through the 5 year-period covered by the contract, for minimum anticipated revenues of 48 million euros ($53.73 million) from prior 34 million euros .Of minimum anticipated revenues of 48 million euros, around 14 million euros have already been received.  Full Article

Molmed H1 net loss narrows to EUR 8.4 mln
Monday, 1 Aug 2016 12:31pm EDT 

Molmed Spa : H1 total revenue 10.2 million euros ($11.39 million) versus 7.2 million euros a year ago .H1 net loss 8.4 million euros versus loss 11.2 million euros a year ago.  Full Article

Oxford BioMedica grants to MolMed non-exclusive licence under its LentiVector platform technology
Tuesday, 7 Jun 2016 02:53am EDT 

Molmed Spa : Signs with Oxford BioMedica new non-exclusive licence agreement concerning lentiviral vector technology . Oxford BioMedica grants to Molmed non-exclusive licence under its LentiVector platform technology for manufacturing and development services . At the same time, the parties terminated the agreement dated 10 December 2004 under which Oxford BioMedica granted MolMed a world-wide, exclusive licence on development and commercialisation of certain products in the field of genetically modified T lymphocytes transduced with retroviral vectors used in research and ex vivo gene therapy, including Zalmoxis .As a result of this agreement settlement, MolMed owes no outstanding royalties to Oxford BioMedica while keep using the above mentioned technology, in the ongoing development and potential commercialization of Zalmoxis.  Full Article

More From Around the Web

BRIEF-MolMed and Rocket Pharma sign collaboration agreement for treatment of Fanconi Anemia

* MolMed and Rocket Pharma establish a collaboration agreement in the field of gene therapy for the treatment of Fanconi Anemia